PHRI has received a $244,800 grant from the Canadian Institutes of Health Research (CIHR) for a new study that aims to improve treatment for patients with chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease that can lead to amputations and other major complications.
Co-led by Senior Scientist Sanjit Jolly and Research Fellow Marc-André d’Entremont, the CLARITY trial will explore whether an intravascular ultrasound (IVUS) guided strategy is safe, effective, and can reduce severe adverse events like above-ankle amputations in CLTI patients undergoing revascularization.
Marc-André d’Entremont
“Given the current high rates of recurrent revascularization and amputations in CLTI, improving outcomes after the index revascularization would have a significant public health impact,” said d’Entremont.
The trial’s vanguard phase will assess the feasibility of conducting a larger multicenter study. It will initially enroll 100 patients from across Canada and the United States, with the first patient expected to be enrolled this summer.
“In CLARITY we aim to explore how IVUS can improve revascularization procedures and reduce adverse events for patients facing the threat of limb loss,” added d’Entremont. “This grant will help us move forward with this study and work toward better outcomes and quality of life for these high-risk patients.”
